Literature DB >> 26847322

Evaluation of muscle strength and manual dexterity in patients with Charcot-Marie-Tooth disease.

Alena Kobesova1, Marcela Nyvltova2, Josef Kraus3, Pavel Kolar2, Angela Sardina4, Radim Mazanec5, Ross Andel4.   

Abstract

STUDY
DESIGN: Matched pair study.
INTRODUCTION: Differences in hand-muscle strength/dexterity between dominant (DH) and non-dominant (NDH) hand in Charcot-Marie-Tooth disease (CMT) are not well understood. PURPOSE OF THE STUDY: To compare muscle strength/dexterity between DH and NDH and to correlate manual dexterity, strength and sensory function. PATIENTS AND METHODS: Thirty CMT patients were studied using functional muscle testing (FMT) and strength (dynamometry), dexterity (the Nine Hole Peg Test [NHPT]), and Jebsen-Taylor Hand Function [JTT]), and sensory function (the Nottingham Sensory Assessment [NSA]).
RESULTS: Scores were worse for DH than NDH on FMT (p = 0.043) and NHPT (p = 0.014) but not on JTT (p = 0.098), handgrip strength (p = 0.710) or tripod pinch (p = 0.645). NSA did not correlate significantly with any tests (p's0.05).
CONCLUSIONS: In CMT disease, DH appears more impaired than NDH in terms of function and dexterity. Greater muscle weakness in DH may also emerge as CMT progresses. LEVEL OF EVIDENCE: 3b.
Copyright © 2016 Hanley & Belfus. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Charcot-Marie-Tooth disease; Hand strength; Hereditary motor and sensory neuropathy; Manual dexterity; Sensory function

Mesh:

Year:  2015        PMID: 26847322     DOI: 10.1016/j.jht.2015.12.002

Source DB:  PubMed          Journal:  J Hand Ther        ISSN: 0894-1130            Impact factor:   1.950


  1 in total

1.  Chemotherapy-Induced Peripheral Neuropathy Detection via a Smartphone App: Cross-sectional Pilot Study.

Authors:  Ciao-Sin Chen; Judith Kim; Noemi Garg; Harsha Guntupalli; Reshma Jagsi; Jennifer J Griggs; Michael Sabel; Michael P Dorsch; Brian C Callaghan; Daniel L Hertz
Journal:  JMIR Mhealth Uhealth       Date:  2021-07-05       Impact factor: 4.947

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.